A Phase I, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 anti-LAG-3 mAb Administered Alone or in Combination with REGN2810 anti-PD-1 mAb in Patients with Advanced Malignancies

Brief Summary

Type:
Other

Study Type:
Treatment

Phase:
I

ClinicalTrials.gov Identifier:
NCT03005782

Study #:
STUDY00141280

Start Date:
Jul 15, 2018

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT03005782

View Complete Trial Details & Eligibility at ClinicalTrials.gov